We designed a comprehensive 42‐marker mass cytometry panel to profile the peripheral blood samples from 57 patients diagnosed with advanced HER2‐negative breast cancer receiving anti‐PD‐1 combination therapy. This evidence concerns the gene ERBB2 and breast carcinoma.